静脉注射免疫球蛋白治疗脓毒症诱导凝血病的综合疗效分析:单中心回顾性观察研究
该单中心回顾性对照研究纳入赣州市人民医院2016年1月至2022年12月230例脓毒症诱导凝血病(SIC)患者,经倾向性评分匹配后分为试验组(n=115)与对照组(n=115),均按SSC2016指南治疗,试验组入院后接受静脉注射免疫球蛋白(IVIg)200 mg/kg·d连续3天。结果显示试验组第5天凝血因子II、X恢复更快,第7天血小板及血栓弹力图最大振幅(MA)显著升高,凝血指标恢复更快,APACHE II、SOFA、DIC评分及乳酸下降更明显,ICU停留、机械通气及连续肾脏替代治疗时间更短,28天生存率更高(P<0.05)。作者结论认为IVIg可提高血小板计数和凝血因子水平、纠正凝血紊乱、改善器官功能并降低28天死亡率。
要点
- 单中心回顾性研究纳入230例SIC患者,倾向性评分匹配后试验组与对照组各115例,试验组接受IVIg 200 mg/kg·d连续3天。
- 第3天两组血小板及TEG最大振幅(MA)均下降,对照组下降更显著(P<0.05);第7天试验组显著升高(P<0.05)。
- 凝血因子II、X第3天开始升高,试验组第5天恢复正常更快(P<0.05);PT、INR、APTT、D-二聚体、纤维蛋白原、FDP、TEG-R、TEG-K第3天明显下降,试验组第5天恢复更快(P<0.05)。
- 第3天两组APACHE II、SOFA、DIC评分及乳酸均下降,试验组第7天下降更显著(P<0.05);试验组白细胞计数、CRP、降钙素原、IL-6、Tmax更低(P<0.05)。
- 试验组ICU停留、机械通气及连续肾脏替代治疗时间更短(P<0.05),28天生存率更高(P<0.05);两组发热时间及血管活性药物使用时间无显著差异。
适用人群与场景
- 赣州市人民医院2016年1月至2022年12月收治的230例脓毒症诱导凝血病(SIC)患者,均按SSC2016指南治疗。
- 经倾向性评分匹配后分为试验组(n=115)和对照组(n=115)。
处置流程与药物剂量
- 试验组在入院后接受IVIg 200 mg/kg·d,连续3天。
- 两组均按SSC2016指南治疗。
研究设计与关键结果
- 研究类型:单中心、回顾性观察性对照研究;样本量230例,倾向性评分匹配后试验组115例、对照组115例。
- 干预与对照:试验组接受IVIg 200 mg/kg·d连续3天,对照组未接受IVIg,两组均按SSC2016指南治疗。
- 第3天两组血小板及TEG最大振幅(MA)均下降,对照组下降更显著(P<0.05);第5天两组均恢复,第7天试验组显著升高(P<0.05)。
- 凝血因子II、X第3天开始升高,试验组第5天恢复正常更快(P<0.05)。
- PT、INR、APTT、D-二聚体、纤维蛋白原、FDP、TEG-R、TEG-K第3天明显下降,试验组第5天恢复显著更快(P<0.05)。
- 第3天两组APACHE II、SOFA、DIC评分及乳酸均下降,试验组第7天下降更显著(P<0.05)。
- 试验组白细胞计数、CRP、降钙素原、IL-6、Tmax水平更低(P<0.05)。
- 试验组ICU停留时间、机械通气时间及连续肾脏替代治疗时间更短(P<0.05);两组发热时间及血管活性药物使用时间无显著差异。
证据类型、等级与局限
- 证据类型:单中心、回顾性观察性对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,IVIg可成功提高SIC患者血小板计数和凝血因子水平、纠正凝血紊乱、增强器官功能并降低28天死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objective : The aim of the study is to investigate the efficacy of intravenous immunoglobulin (IVIg) in treating sepsis-induced coagulopathy ( SIC ). Methods : A retrospective controlled analysis was conducted on 230 patients with SIC at Ganzhou People's Hospital from January 2016 to December 2022. All patients were screened using propensity score matching and treated according to the SSC2016 guidelines. Compared with the control group (n = 115), patients in the test group (n = 115) received IVIg (200 mg/kg.d) for 3 consecutive days after admission. The rating scales, coagulation function, survival, and treatment duration were evaluated. Results : On day 3 of treatment, both groups exhibited reduced platelet and thromboelastogram (TEG) maximum amplitude (MA) levels, with the control group showing a more significant decrease ( P < 0.05). By the fifth day, these levels had recovered in both groups. However, the test group experienced a significant increase by day 7 ( P < 0.05). Coagulation factors II and X began to increase on day 3, and normalization was significantly faster in the test group on day 5 ( P < 0.05). The levels of prothrombin time, international normalized ratio, activated partial thromboplastin time, d -dimer, fibrinogen, fibrin degradation products, TEG-R, and TEG-K exhibited a notable decline on day 3 and demonstrated significantly faster recovery on day 5 in the test group ( P < 0.05). In addition, both groups showed a reduction in Acute Physiology and Chronic Health Evaluation II, Sequential Organ Failure Assessment, disseminated intravascular coagulation, and lactate (LAC) levels on day 3, but the test group's scores decreased significantly more by day 7 ( P < 0.05). Within the test group, white blood cell count, C-reactive protein, procalcitonin, IL-6, and Tmax levels were lower ( P < 0.05). Furthermore, the test group demonstrated shorter duration for intensive care unit stay, mechanical ventilation, and continuous renal replacement therapy ( P < 0.05). No significant differences were observed in the duration of fever or vasoactive drug use between the groups. However, the log-rank method indicated a higher 28-day survival rate in the test group ( P < 0.05). Conclusion : IVIg can successfully increase platelet count and coagulation factors, correct coagulation disorders, enhance organ function, and reduce 28-day mortality in patients with SIC .
参考来源
- Fang J, Huang P, Cui W, et al. COMPREHENSIVE THERAPEUTIC EFFICACY ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN IN TREATING SEPSIS-INDUCED COAGULOPATHY: A SINGLE-CENTER, RETROSPECTIVE OBSERVATIONAL STUDY. Shock. 2024. PMID: 38321608. doi:10.1097/SHK.0000000000002336
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。